For years, targeted protein degradation was biotech’s most exciting “almost.” The science was elegant, the promise was huge, but it had never produced an approved drug, so skeptics could dismiss it as a platform in search of a product. That changed in 2026 with the first-ever approval of a PROTAC degrader, a genuine milestone that turned the modality from promise into proven reality. So is targeted protein degradation the next big thing in drug development? Here is a clear-eyed look.
What targeted protein degradation is
Conventional drugs mostly work by inhibiting a disease-causing protein, binding to it and blocking its activity. Targeted protein degradation takes a fundamentally different approach: instead of just blocking the protein, it destroys it, harnessing the cell’s own natural disposal system (the ubiquitin-proteasome system) to tag the target for elimination. This matters for two big reasons. First, removing a protein entirely can be more complete and durable than merely inhibiting it. Second, and more importantly, degradation can hit targets that were considered “undruggable” by traditional inhibitors, because it does not require the deep binding pocket that a classic drug needs. That ability to go after previously unreachable targets is the heart of the excitement.
PROTACs and molecular glues
Two main flavors of degrader lead the field. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules with two ends, one that grabs the target protein and one that recruits the cell’s disposal machinery, physically bringing them together so the target is destroyed. Molecular glues are smaller molecules that work by “gluing” the target to the disposal machinery, often with advantages in size and drug-like properties. Both are advancing in the clinic, and beyond them a whole toolbox of newer approaches is emerging, aimed at degrading proteins in different locations and ways. The field has matured from a single clever idea into a rich platform of related technologies.
The milestone that changed everything
The defining event was the FDA approval of the first PROTAC degrader, developed by Arvinas with partner Pfizer, for a form of advanced breast cancer. After more than a decade of work, this validated that a rationally designed protein degrader can travel all the way from concept to approved medicine, a watershed for the entire field. An approval does not by itself prove the modality will be broadly transformative, but it decisively answers the skeptics’ core objection. Targeted protein degradation is no longer theoretical; it is a class with a marketed drug.
Who leads the field
A cluster of companies has built the modality, and their progress is worth watching.
- Arvinas, the PROTAC pioneer, now has both an approved degrader and a deep pipeline, including a brain-penetrant degrader targeting a protein implicated in Parkinson’s disease that has shown encouraging early clinical results, an especially exciting prospect given how hard neurodegeneration has been to drug.
- Kymera Therapeutics is a leader in applying degraders beyond oncology, advancing oral degraders for immune and inflammatory diseases, an area where an oral drug could compete with injected biologics, and it has attracted major pharma partnerships.
- Nurix, Monte Rosa, C4 Therapeutics, and others are advancing their own degrader and molecular-glue programs, and big pharma, including Novartis, Gilead, Sanofi, and Pfizer, has struck a series of deals to get access to the technology.
Beyond oncology
Although degraders began in cancer, one of the most important trends is their expansion into immunology, inflammation, and neuroscience. The ability to degrade previously undruggable targets, including transcription factors and proteins inside the brain, opens doors across medicine. An oral degrader that matches the effect of an injectable biologic in an inflammatory disease, or one that can reach a target inside the brain, would be genuinely differentiated. This broadening beyond oncology is a big part of why enthusiasm for the modality has grown, and it is where much of the next wave of clinical data will come from.
So, is it the next big modality?
The honest answer is a qualified yes. The case in favor is strong: the science is validated by a first approval, the modality can reach targets others cannot, big pharma is investing heavily, and the pipeline is broadening across diseases. The case for caution is equally real: most degrader programs are still early, one approval does not make a category, and, as with any new modality, there will be failures and hard lessons as it scales. The most balanced view is that targeted protein degradation has crossed the crucial threshold from promise to proven and is now one of the most important emerging modalities in drug development, without yet having proven it will be as transformative as its biggest champions hope. The next few years of clinical data, especially outside oncology, will tell. For now, it has firmly earned its place among the technologies most worth watching.
The challenges the field still has to solve
For all the excitement, targeted protein degradation faces real hurdles that will determine how far it goes, and a balanced view has to take them seriously. One is the machinery the approach depends on: degraders work by recruiting the cell’s disposal system, and the specific components they hijack are limited in number and not active everywhere in the body, which constrains where and how degraders can work. Expanding the toolkit of usable machinery is an active area of research. Another challenge is resistance, since cancers in particular are adept at evolving ways to evade therapies, and degraders will face the same pressure as they are used more widely. There are also the practical difficulties common to any novel modality: designing degraders with the right drug-like properties can be hard, some are large and complex molecules that are challenging to turn into convenient medicines, and manufacturing and formulation bring their own hurdles. Selectivity and safety matter enormously too, because destroying a protein completely, rather than just dialing it down, raises the stakes if the drug hits the wrong target. And the field faces an increasingly crowded and complex intellectual property landscape, as many companies race to patent the components and methods involved. None of these challenges is necessarily fatal, and the first approval shows they can be overcome for the right target, but they are the reason for measured optimism rather than unbridled hype. The companies that solve these problems, better machinery, cleaner selectivity, more drug-like molecules, will be the ones that turn a promising modality into a broad, durable class of medicines.
How to evaluate a degrader company
For investors and potential partners trying to separate substance from hype in this field, a few questions cut to the heart of it. Does the company have programs actually advancing in the clinic with real human data, or mostly a platform and a pitch? How differentiated is its technology, does it have genuinely novel capabilities, such as access to targets or tissues others cannot reach, or is it one of many pursuing crowded, well-trodden targets? Is it expanding thoughtfully beyond oncology into areas like immunology and neuroscience, where the modality’s unique strengths could be most valuable? How strong is its intellectual property position in an increasingly crowded patent landscape? And has serious pharma validated it through partnerships, and if so, have those partners deepened their commitment over time? The first approval in the field has proven the modality can work, which shifts the question from whether degraders are real to which companies will actually build durable value with them. Applying these questions, rather than being swept up in the excitement of a validated new modality, is how to identify the players most likely to turn the promise into approved medicines and lasting businesses.
To follow the readouts, approvals, and deals shaping this modality, the BioMed Nexus daily brief tracks it as it develops, and for the computational side of designing these molecules, see the companies in our AI drug discovery directory, since degrader design increasingly draws on advanced computational tools.
Frequently asked questions
What is targeted protein degradation?
Targeted protein degradation is a drug modality that destroys a disease-causing protein rather than just inhibiting it, by harnessing the cell's natural disposal system to tag the protein for elimination. It can reach targets considered undruggable by traditional inhibitors, because it does not require the deep binding pocket a classic drug needs.
What is the difference between a PROTAC and a molecular glue?
Both are protein degraders. A PROTAC is a bifunctional molecule with one end that grabs the target protein and another that recruits the cell's disposal machinery, bringing them together. A molecular glue is a smaller molecule that glues the target to the disposal machinery directly, often with more favorable drug-like properties.
Has a protein degrader drug been approved?
Yes. In 2026 the FDA approved the first-ever PROTAC degrader, developed by Arvinas with Pfizer, for a form of advanced breast cancer. After more than a decade of work, this validated that a rationally designed protein degrader can travel from concept to approved medicine, a major milestone for the whole field.
